Mucoepidermoid carcinoma of the lung is a rare malignancy of salivary gland-type origin. We report a case of a 21-year-old man with a right mainstem bronchus mass composed predominantly of clear cells. This case represents a rare primary pulmonary low-grade mucoepidermoid carcinoma positive for MAML2 rearrangement by fluorescence in situ hybridization with a prominent clear cell component. P rimary pulmonary mucoepidermoid carcinoma (PMEC) is a rare malignant neoplasm representing 0.1% to 0.2% of all primary pulmonary carcinomas (1) (2) (3) (4) (5) . It typically arises in the minor salivary glandtype epithelium of the large central airways (2) (3) (4) (5) . Occasionally, mucoepidermoid carcinoma (MEC) demonstrates prominent cytoplasmic clearing (6) (7) (8) (9) (10) , and on biopsy, the presence of these clear cells can pose a diagnostic challenge for pathologists. We present a case of PMEC with prominent clear cells.
CASE DESCRIPTION
A 21-year-old man presented to his primary care physician with a persistent cough producing blood-tinged sputum. Th e initial chest x-ray was unremarkable but over the next 3 months the patient's cough continued to worsen, progressing to moderate hemoptysis. A computed tomography (CT) scan of the chest revealed a 2.5 cm mass within the right mainstem bronchus (Figure 1 ). Rigid bronchoscopy with biopsy of the mass was performed. Th e hematoxylin and eosin-stained sections of the biopsy yielded a neoplasm composed of large epithelioid cells with clear cytoplasm and round-to-oval nuclei with inconspicuous nucleoli. By immunohistochemistry, the tumor cells were positive for pan keratin, EMA, CK7, and vimentin. Th e tumor cells were negative for PAX8, CD10, RCC, CAIX, HMB45, TTF1, S100, CDX2, inhibin, OCT4, p40, p63, CK5/6, CK20, calponin, chromogranin, and synaptophysin. EGFR polymerase chain reaction (PCR) revealed a mutation in exon 18. Based on the available biopsy material and following expert consultation, the biopsy was diagnosed as non-small cell carcinoma with clear cell features.
Eight months following initial presentation, a right-sided thoracotomy and sleeve right upper lobectomy were performed. Gross examination revealed a 2.3 × 2.2 × 1.6 cm well-delineated mass protruding into the bronchial lumen. Microscopic examination ( Figure 2 ) showed a mass situated in the submucosa of the bronchial wall without invasion into the lung parenchyma. In addition to the dominant population of clear cells, the tumor had foci of gland formation with mucin, squamoid cells, and intermediate cells. Th ere was no increased mitotic activity or keratinization, but scattered calcifi cations were apparent. Fluorescence in situ hybridization (FISH) was positive for MAML2 rearrangement and negative for EWSR1 rearrangement ( Figure 3) . Th e microscopic features and ancillary tests supported the diagnosis of low-grade PMEC.
Th e patient tolerated the lobectomy well and was discharged without complications or adjuvant therapy. At 15 months following lobectomy, the patient exhibited no recurrence or metastasis. Th e patient continued with surveillance bronchoscopy and chest CT scans every 6 months for 5 years.
DISCUSSION PMEC is a rare malignant neoplasm typically aff ecting patients <30 years of age, although the age range is wide (2) (3) (4) .
Most patients present with symptoms of large airway irritation or obstruction including cough, hemoptysis, wheezing, chest pain, and obstructive pneumonia (2) (3) (4) 11) . PMEC may be missed on chest radiographs; however, CT imaging typically demonstrates a well-defi ned endobronchial mass (2, 3) . PMEC is frequently positron emission tomography avid (3) .
PMEC is composed of varying proportions of mucus-secreting cells, intermediate cells, and epidermoid (or squamoid) cells, lacking keratinization and/or in situ carcinoma of the overlying epithelium (2, 3, 5) . Th e tumor cells display various patterns of growth, including mucin-filled cysts, nests, islands, and tubules or glands (2-4). Occasionally stromal calcifications with or without a granulomatous reaction are also observed in areas of mucous extravasation (3, 11) . Immunophenotypically, PMEC is positive for pan cytokeratin, CK7, CK5/6, p63, and p40. S100, CEA, and EMA show variable staining. PMEC is negative for CK20, TTF1, SOX 10, napsin A, androgen receptor, calponin, SMA, and smooth muscle myosin heavy chain (3) (4) (5) (6) 12) .
PMEC is associated with a translocation involving CRTC1 (also known as MECT1) on 19p13 and MAML2 on 11q21 in at least a subset of cases. Identifi cation of the CRTC1-MAML2 fusion gene is now considered to be pathognomonic for this entity, and the fusion gene can be detected by real-time PCR or FISH in both low-grade and high-grade MEC (3, 5, 7, 8, 13, 14) . Recent studies of PMEC demonstrate MAML2 rearrangement in 60% to 100% of tested cases (5, 15, 16) detected by FISH or real-time PCR. Additionally, there are documented reports of EGFR mutations in PMEC with involvement of exon 18 (L861Q) (3, 17) . Other studies demonstrated EGFR expression without EGFR amplifi cation or mutation (18) .
Diff erentiating between squamous cell carcinoma (SCC) and PMEC is challenging, considering the overlap in the immunophenotype (both are keratin, p63, and p40 positive). Although not specifi c, features more frequently observed in high-grade PMEC than SCC are 1) exophytic endobronchial growth, 2) absence of carcinoma in situ, and 3) absent keratinization and squamous pearl formation (3). Pulmonary adenocarcinoma is typically positive for TTF1, CK7, and napsin A and negative for CK20 and p63. Adenosquamous carcinoma of the lung exhibits a mixture of adenocarcinoma (TTF1 positive) and SCC (p63 positive). Metastatic carcinoma, such as clear cell renal cell carcinoma, is excluded using immunostains such as RCC and CD10, although these stains alone are not specifi c. More importantly, renal cell carcinoma is excluded using MAML2 FISH, radiographic imaging demonstrating a lack of a renal mass, and/or the presence of mucin-containing cells. Perivascular epithelioid cell tumor is positive for HMB45, MART1, melanA, SMA, and desmin. Hyalinizing clear cell carcinoma (HCCC) contains clear cells and mucin-producing cells. HCCC is diff erentiated from PMEC using FISH, as HCCC is positive for EWSR1-ATF1 fusion.
Using the current World Health Organization classifi cation, PMEC is subclassifi ed into low-grade and high-grade. Most cases are low-grade PMEC and have an excellent prognosis, while high-grade PMEC behaves similarly to other non-small cell carcinomas of the lung (2, 3, 5) . Treatment for PMEC is surgical resection (2, 4, 19) , with a low rate of recurrence for patients with a low-grade tumor (20, 21) . PMEC is a rare primary malignancy in the lung with a spectrum of morphologies that might include a predominance of clear cells. In diagnostically challenging cases, FISH or realtime PCR might identify MAML2 rearrangement, which is a MEC-specifi c genetic abnormality previously identifi ed in a subset of PMEC.
